Drug Trial Radar · NCT05279859
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 15, 2022
Primary completion
Mar 1, 2025
Study completion Jun 1, 2025
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the preliminary efficacy of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
Conditions
- Acute Myeloid Leukemia
Interventions
ERAS-007Drug
Administered orally
ERAS-601Drug
Administered orally
GilteritinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
- Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 29
- Recommended Dose (RD)Time frame: Study Day 1 up to Day 29
- Adverse EventsTime frame: Assessed up to 24 months from time of first dose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Texas Oncology
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology Virginia
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.